News
Cytek Biosciences to Report Second Quarter 2024 Financial Results on August 6, 2024
Cytek Biosciences, Inc.
FREMONT, Calif., July 30, 2024 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analytics solutions company, today announced that it will release second-quarter 2024 financial results after the market closes on Tuesday, August 6, 2024. The Company’s management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook.
Live audio of the webcast will be available in the “Investors” section of the Company’s website at investors.cytekbio.com.
About Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company that is advancing the next generation of cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis using its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s new approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with accuracy and sensitivity. Cytek’s platform includes its flagship instruments, the Cytek Aurora™ and Northern Lights™ systems; its cell sorter, the Cytek Aurora CS; its flow cytometer and imaging products under the Amnis® and Guava® brands; the Cytek Orion™ reagent cocktail preparation system; and reagents, software and services to provide a comprehensive, integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California, with offices and distribution channels throughout the world. More information about the company and its products is available at www.cytekbio.com.
Cytek products are for research use only and not for use in diagnostic procedures (except for the Cytek Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Amnis and Guava are registered trademarks of Cytek Biosciences, Inc.
In addition to its Securities and Exchange Commission (SEC) filings, press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account (formerly Twitter) as channels for distributing information about its company, products, planned financial and other announcements, participation in upcoming investor and industry conferences and other matters. This information may be considered material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page and X account, in addition to its SEC filings, press releases, public conference calls and webcasts.
The story continues
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
Contact the investor:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com